Table 4.

Cancer characteristics for supplemental and primary US screening for breast cancer

Author, year	Method	Proportions of invasive cancers, %		Proportions of node-negative invasive cancers, %
		Number	95% CI	Number	95% CI
Supplemental US screening studies
Tagliafico, 2016 [21]	Supplemental US	22/23	95.7(76.0–99.8)	13/20	65.0(40.9–83.7)
Kim, 2016 [22]	Supplemental US	7/9	77.8(40.2–96.1)
Weigert, 2015 [26]	Supplemental US	10/22	45.5(25.1–67.3)
Hwang, 2015 [25]	Supplemental US	7/8	87.5(46.7–99.3)
Moon, 2015 [24]	Supplemental US	2/4	50.0(15.0–85.0)	1/2	50.0(9.5–90.5)
Leong, 2012 [32]	Supplemental US	1/2	50.0(9.5–90.5)
Hooley, 2012 [31]	Supplemental US	2/3	66.7(12.5–98.2)	2/2	100.0(19.8–100.0)
Joint screening studies
Dong, 2017 [9]	Primary MAM	30/63	47.6(35.0–60.5)	16/30	53.3(34.6–71.2)
	Primary US	25/46	54.3(39.2–68.8)	13/25	52.0(31.8–71.7)
Ohuchi, 2016 [10]	Primary MAM	73/117	62.4(52.9–71.0)	54/73	74.0(62.2–83.2)
	Primary US	111/143	77.6(69.7–84.0)	89/111	79.3(70.3–86.2)
Berg, 2016 [11]	Primary MAM	41/59	69.5(56.0–80.5)
	Primary US	53/58	91.4(80.3–96.8)
Brem, 2015 [39]	Primary MAM	51/82	62.2(50.8–72.5)	46/48	95.8(84.6–99.3)
	Primary US	73/95	76.8(66.8–84.6)	65/69	94.2(85.1–98.1)
Huang, 2012 [30]	Primary MAM	24/28	85.7(66.4–95.3)
	Primary US	22/23	95.7(76.0–99.8)
Kelly, 2010 [40]	Primary MAM	17/23	73.9(51.3–88.9)
	Primary US	35/38	92.1(77.5–97.9)
Wilczek, 2016 [38]	Primary MAM	5/7	71.4(30.3–94.9)
	Primary US	9/11	81.8(47.8–96.8)
Venturini, 2013 [29]	Primary MAM	8/12	66.7(35.4–88.7)
	Primary US	2/2	100.0(19.8–100.0)
Weinstein, 2009 [35]	Primary MAM	3/7	42.9(11.8–79.8)	3/3	100.0(31.0–100.0)
	Primary US	3/3	100.0(31.0–100.0)	3/3	100.0(31.0–100.0)
Honjo, 2007 [37]	Primary MAM	5/8	62.5(25.9–89.8)	4/5	80.0(29.9–98.9)
	Primary US	7/7	100.0(56.1–100.0)	6/7	85.7(42.0–99.2)

CI Confidential interval;MAM Mammography; US Ultrasonography